Entrada Therapeutics, Inc.

NASDAQ
TRDA
paper.types.company
Rentabilité sur six mois: -61.17%
Rendement en dividendes: 0%
Secteur: Healthcare

7.7 $

0 $ 0%
7.5 $
21.59 $

paper.min_max_per_year

Calendrier des promotions Entrada Therapeutics, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Entrada Therapeutics, Inc.

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs.

plus de détails
The company's lead therapeutic candidates, which include ENTR-601-44 and ENTR-601-45, which are in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1; ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy; and ENTR-701, which is in preclinical trail for the treatment of myotonic dystrophy type 1. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Paramètres de base

IPO date
2021-10-29
ISIN
US29384C1080
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
lien
Tous les paramètres

Grade

Sous-estimation
Nom Signification Grade
P/S 3.2 5
P/BV 1.57 8
P/E 10.28 9
Efficacité
Nom Signification Grade
ROA 13.18 4
ROE 19.56 6
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA 1.26 8
Debt/Ratio 0.1125 10
Debt/Equity 0.2278 10
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % 734.45 10
Rentabilité Ebitda, % -278.75 0
Rentabilité EPS, % -230.43 0
Plus de détails

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 7.7 $ 0 $ 0 $ 0 % 0 % 0 %
common.calendar.number_days.7d 7.69 $ 0 $ 0 $ 0.13 % 0 % 0 %
common.calendar.number_days.30d 8.87 $ 7.5 $ 8.24 $ -13.19 % 0 % 0 %
common.calendar.number_days.90d 12.02 $ 7.5 $ 10.81 $ -35.94 % 0 % 0 %
common.calendar.number_days.180d 19.83 $ 7.5 $ 18.45 $ -61.17 % 0 % 0 %
common.calendar.number_days.1y 15.39 $ 7.5 $ 21.59 $ -49.97 % 0 % 0 %
common.calendar.number_days.3y 6.27 $ 7.5 $ 22.79 $ 22.81 % 0 % 0 %
common.calendar.number_days.5y 0 $ 5.49 $ 35 $ 0 % 0 % 0 %
common.calendar.number_days.10y 0 $ 5.49 $ 35 $ 0 % 0 % 0 %
common.calendar.number_days.ytd 18.01 $ 7.5 $ 18.31 $ -57.25 % 0 % 0 %

Principaux propriétaires

Entreprises similaires

P/E & P/BVEV/Ebitda & Debt/Ebitda


Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Mr. Dipal Doshi CEO & Director 968.21k 1976 (49 années)
Mr. Nathan J. Dowden President & COO 694.3k 1971 (54 année)
Dr. Natarajan Sethuraman Ph.D. Chief Scientific Officer 694.3k 1962 (63 année)
Mr. Kory James Wentworth CPA CFO & Treasurer N/A 1979 (46 années)
Dr. Jared Cohen J.D., Ph.D. General Counsel N/A
Ms. Kerry Robert M.S. Senior Vice President of People N/A
Ms. Karla MacDonald Chief Corporate Affairs Officer N/A
Mr. Kevin Healy Ph.D. Senior Vice President of Regulatory Affairs N/A

Informations sur l'entreprise

Adresse: United States, Boston. MA, 6 Tide Street - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.entradatx.com